We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » New Data Suggests Keytruda Is Effective When Taken Half as Often for Melanoma
New Data Suggests Keytruda Is Effective When Taken Half as Often for Melanoma
Merck said its oncology blockbuster Keytruda (pembrolizumab) is just as safe and effective in a dose of 400 mg every six weeks for first-line treatment of melanoma as at the approved dosing regimen of 200mg every three-weeks.